Pfizer, Mylan announce two future Viatris Board Members
Ian Read and James Kilts offer strong experience to support long-term value creation
Pfizer and Mylan announced that Ian Read…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Mylan
USFDA approves Biocon’s sBLA for Pegfilgrastim new manufacturing facility
Expanded capacity will enable greater patient access globally
Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination
Formed through a combination of two complementary businesses, Viatris will unite Upjohn’s strong leadership position in China and…
Biocon features in the ASIA IP ELITE list for the fourth consecutive year
Biocon Biologics debuts on the ASIA IP ELITE 2019 list
Novartis gets US nod for long-delayed Amgen copycat
Novartis's biosimilar, called Ziextenzo, is aimed at helping cancer patients boost infection-fighting white blood cells during…
Mylan working with DCGI to launch new TB drug in India
Mylan will be in a position to launch the product in India soon after receiving approvals from DCGI," Mylan's Global President and…
Mylan to invest $1 billion in India on capex in six years
Currently Mylan has 21 facilities and 15,000 employees working in India
Multinational drug company Mylan will invest $1 billion…
Eisai India and Mylan to commercialise teceris
The second eribulin brand in India, teceris aimed at expanding access to metastatic breast cancer patients in India
Big Pharma to get bigger, but what about patients?
The second patent cliff is around the corner, as patents for branded molecules with cumulative global sales of over $ 251 billion…
Panel discussion: From formulation development to commercialisation of complex generics: Challenges…
FDD Conclave, a one-of-its-kind platform for formulation development and drug delivery professionals, is a thought leadership…